SCHEMBL2215562

SCHEMBL2215562

CC(C)(C)OC(=O)NCC(C(=O)Nc1cccc(Nc2nc(-c3cccc4c3oc3ccccc34)cc3ccnn23)c1)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SUV39H2 Q9H5I1 1/20 0.34
BRD4 O60885 2/20 0.31
MAPK1 P28482 2/20 0.31
ALDH1A1 P00352 2/20 0.31
LMNA P02545 2/20 0.31
HPGD P15428 2/20 0.31
PKM P14618 1/20 0.31
TSHR P16473 1/20 0.31
CCKBR P32239 1/20 0.31
CYP1A2 P05177 1/20 0.30
CYP3A4 P08684 1/20 0.30
CYP2C9 P11712 1/20 0.30
CYP2C19 P33261 1/20 0.30
KDM4E B2RXH2 1/20 0.30
MEN1 O00255 1/20 0.30
HTT P42858 1/20 0.30
KMT2A Q03164 1/20 0.30
NCOA1 Q15788 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
NCOA3 Q9Y6Q9 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2215331 0.90 SRC (0.33) MAPK1ALDH1A1LMNAHPGDPKM
SCHEMBL2213533 0.88 ROCK2 (0.35) MAPK1TSHRMEN1KMT2ANCOA1
SCHEMBL2212145 0.85 BRD4 (0.39) BRD4CCKBR
SCHEMBL2214458 0.82 ROCK2 (0.42) MAPK1ALDH1A1
SCHEMBL2215145 0.80 BRD4 (0.36) BRD4ALDH1A1CCKBR
SCHEMBL2214770 0.78 NAMPT (0.34) BRD4ALDH1A1LMNAHPGDKDM4E
SCHEMBL2214698 0.76 BRD4 (0.38) BRD4MAPK1CCKBRCYP1A2KDM4E
SCHEMBL2215249 0.75 SMN1; SMN2 (0.37) MAPK1ALDH1A1LMNAHPGDTSHR
SCHEMBL2214311 0.75 KCNK9 (0.44) ALDH1A1LMNAHPGDKDM4EMEN1
SCHEMBL2213364 0.75 NAMPT (0.36) BRD4MAPK1TSHRCCKBRCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1797096-B1 PYRAZOLOPYRIMIDINES AS INHIBITORS OF PROTEIN KINASE B (AKT) BAYER SCHERING PHARMA AG (DE) 2011-07-27 EP disclosed
US-7745446-B2 Pyrazolo[1,5-c]pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-06-29 US disclosed
US-20070254046-A1 Novel Pyrazolopyrimidines ALTANA PHARMA AG (DE) 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254046-A1 Novel Pyrazolopyrimidines MCL1, RARS2, CDK4 SUV39H2 3665/4885BRD4 708/4885MAPK1 1324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.